STRM.BIO is a biotechnology company developing a non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of genetic medicines.
Its megakaryocyte-derived vesicle (MV) platform focuses on non-viral gene delivery for hematological diseases and in vivo immune and hematopoietic cell engineering, enabling applications in gene editing, RNA therapeutics, and immune cell engineering.